The following securities that could potentially dilute basic net income (loss) per share in the future were not included in the computation of diluted net income (loss) per share for the periods presented, because to do so would have been antidilutive:


	Three Months Ended March 31,
	2026		2025
Outstanding stock options		19,671,897		11,092,400
Outstanding restricted stock units		—		22,500
Common stock under employee stock purchase plan		549,789		—
Common stock warrants		21,308,618		161,616
Total		41,530,304		11,276,516

The table presented above does not include the number of shares that may be issued upon exercises of the common stock warrants issued in connection with the 2022 Convertible Notes and the 2023 Notes because the number of shares to be issued under these warrants are variable based on a variable exercise price at the warrant holders’ option.